BridGene Biosciences: Funding, Investors & Team (Sep 2026)
BridGene Biosciences is a biotechnology organization utilizing front line chemoproteomic innovation to find and foster little particles. It empowers covalent little particles to perform vast separating live cells, which brings about profoundly specific little atoms that drug customarily undruggable targets.
BridGene Biosciences has raised $66.5M across 2 funding rounds on record, the most recent a Series B of $28.0M announced in Oct 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
BridGene Biosciences Company Profile and Key Stats
Latest funding round on record: Oct 2025.
BridGene Biosciences Funding Rounds
BridGene Biosciences raised $38.5M in a Series B announced in Jul 2022.
3.3 years later, a Series B of $28.0M was announced in Oct 2025.
BridGene Biosciences Founders and Leadership Team
Contact details for the BridGene Biosciences team: 1 of 2 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →BridGene Biosciences Funding Compared to Other Biotechnology Startups
BridGene Biosciences' latest round of $28.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like BridGene Biosciences in Biotechnology and Sunnyvale
Companies Similar to BridGene Biosciences
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
BridGene Biosciences Funding FAQs
What does BridGene Biosciences do?
BridGene Biosciences is a biotechnology organization utilizing front line chemoproteomic innovation to find and foster little particles. It empowers covalent little particles to perform vast separating live cells, which brings about profoundly specific little atoms that drug customarily undruggable targets.
How much funding has BridGene Biosciences raised?
BridGene Biosciences has raised $66.5M across 2 rounds on record. The most recent is a Series B of $28.0M announced in Oct 2025.
When did BridGene Biosciences last raise funding?
BridGene Biosciences' most recent funding round on record is a Series B of $28.0M, announced in Oct 2025.
Who is the CEO of BridGene Biosciences?
Ping C. is listed as CEO at BridGene Biosciences.
Where is BridGene Biosciences headquartered?
BridGene Biosciences is based in Sunnyvale, California, United States.
How many employees does BridGene Biosciences have?
BridGene Biosciences is in the 1-10 employee band.
How does BridGene Biosciences' funding compare to other Biotechnology startups?
BridGene Biosciences' latest round of $28.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's BridGene Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for BridGene Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.